Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
Phase: PHASE2
Conditions: Kidney Injury, Proteinuria, Hypertension
Sponsor: The University of Texas Health Science Center, Houston

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
11 
 
 
 
 
 
 
 
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney 
Injury 
 
NCT04051957  
 
Version Date: 10/24/2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
12 
 
 
1 
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney 
2 
Injury 
3 
4 
SPECIFIC AIM: 
5 
To test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients 
6 
receiving anti-angiogenic therapies that target vascular endothelial growth factor (VEGF). 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
13 
 
 
1 
BACKGROUND  AND  SIGNIFICANCE:Anti-angiogenic  drugs  that  target  VEGF  (bevacizumab) 
2 
and  its  receptors  (sunitinib,  sorafenib,   pazobanib,  and  axitinib)  are  part  of  standard  treatment for 
3 
patients   with   renal   cell   carcinoma, non-small  cell 
lung  carcinoma,   colorectal   carcinoma,  and 
4 
gastrointestinal stromal tumors1.  However, because of their action   on  VEGF  expression  levels,   the 
5 
use  of  these  medications  has  been  associated  with  significant  kidney   damage  and   hypertension. 
6 
Indeed,  the  use  of  anti-angiogenic  therapies  is  frequently  halted  in  cancer  patients  because       of 
7 
worsening  kidney  function,   hypertension, and proteinuria with the subsequent delay, interruption    or 
8 
reduction of effective dose in  patients requiring this treatment modality1. 
9 
Importantly, many of  the  kidney-related side effects of antiangiogenic and anti-VEGF    therapies 
10 
have  been  attributed  to  the  downregulation  of  nitric  oxide  (NO)  bioavailability1.  In  support  of a 
11 
modulatory effect of VEGF  on NO, it has been shown that VEGF infusion results in a significant drop in 
12 
blood pressure mainly through stimulation of eNOS  (endothelial  NO  synthase)  and consequent    NO 
13 
release2,3. 
NO activation and enhanced synthesis lead to vasodilation in the 
r e n a  l 
14 
microvasculature, which results in lowering of blood pressure and other modulatory effects  on   kidney 
15 
function. 
16 
PRELIMINARY STUDIES: Cancer patients receiving anti-VEGF 
therapy share similar 
17 
pathophysiological renal changes as seen in women with preeclampsia8,9.  Endothelial dysfunction in pre- 
18 
eclampsia  results  from  reduction  in  NO  bioavailability  4.  Interestingly,  eNOS  uses  nitrates  as    a 
19 
substrate,  and  hence  several  studies  have   examined   the   utility   of   using   organic  nitrates   as  a 
20 
possible  treatment  for  NO  deficiencies  in  preeclampsia. Although these studies were not powered to 
21 
identify alterations in maternal and fetal outcomes, they did highlight the potential use of organic nitrates 
22 
as antihypertensive agents in pre-eclampsia 5,6,7.  Moreover, recent studies  have shown that NO  donors 
23 
normalize blood pressure in anti-VEGF induced  hypertension10.   The same authors went on  to devise 
24 
a treatment algorithm distinguishing three groups of patients on anti-VEGF treatment: 
25 
normotensive   (<120/<80   mm   Hg);   prehypertensive   (120-130/80-89   mm   Hg)   and hypertensive 
26 
(>140/>90  mm Hg). They suggested no pharmacological treatment for normotensive patients,   starting 
27 
NO donors only  for those pre-hypertensives with evidence of organ damage, and starting with NO 
28 
donors  as  antihypertensive agents for the hypertensives along with weekly blood pressure checks11. In 
29 
their paper, they   suggest  that  pre-treatment  with  long  lasting  NO  donors  may  protect  against  the 
30 
development  of  VEGF  pathway  inhibitor  ( VPI)- induced  hypertension.  They  suggest  the  start of 
31 
treatment  7-10  days  before  the  initiation  of  VPI  therapy.  The  paucity  of  large  clinical  studies in 
32 
t h e   literature  using  NO  donors  to  protect against the development of  proteinuria and hypertension 
33 
and cancer patients receiving VPI therapy prompted us to investigate this modality of treatment. 
34 
RATIONALE OF DOSE:  Preliminary data from a trial done to study single dose effects of isosorbide 
35 
mononitrate (IMN) alone or in combination with losartan on central blood pressure showed that the mean 
36 
placebo-subtracted decrease from baseline in augmentation index was highest in those patients who 
37 
received 60 mg IMN with or without losartan 12.  An effectiveness of extended release nitrate study  for 
38 
treatment of systolic hypertension used 60 mg and 120 mg strength tablets and showed statistically 
39 
significant changes in the augmentation index and decreasing pulse pressure 13. No studies have checked 
40 
the effect on proteinuria. Accordingly, 60 mg and 120 mg of IMN will be used in the present study 
41 
42 
SAFETY OF ISOSORBIDE MONONITRATE: The FDA indication for IMN is for prevention of 
43 
angina pectoris (https://druginserts.com/lib/rx/meds/imdur/). Per the package insert as referenced in 
44 
link, there is no evidence of carcinogenicity, gene mutation or chromosome aberrations at biologically 
45 
relevant concentrations. Side effects include nausea, dizziness, headache, symptomatic hypotension 
46 

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
14 
 
 
1 
2 
MATERIAL AND METHODS: 
3 
Study Population: Adult patients who are referred to the Adult Nephrology Clinic at The   University 
4 
of  Texas  Health  Science Center  at  Houston for  evaluation  and  treatment  of  acute kidney  injury, 
5 
hypertension and/or proteinuria while either on or enrolled with anti-VEGF therapies, will be   included 
6 
in the   study. The protocol is currently being submitted to the University of Texas Health Science 
7 
Center at Houston IRB. Informed consent in the native language of each patient will be obtained prior 
8 
to enrollment. 
9 
Inclusion Criteria: Patients on or enrolled for anti-VEGF therapy and having new-onset proteinuria, 
10 
defined as a urine protein: creatinine ratio (UPC) of >500mg/g or hypertension (Systolic BP ≥ 140   mm 
11 
Hg and/or diastolic BP ≥ 90 mm Hg) or a decrease in eGFR by ≥ 25% from baseline before starting 
12 
therapy. 
13 
Exclusion Criteria: Pregnant women and breast-feeding women. Patients >65 years will be excluded. 
14 
Protocol and Treatment Plan:   The  patients  will  have  baseline  blood pressure (BP),  UPC, weight, 
15 
s e r u m  basic  metabolic      panel and eGFR measured prior to being assigned into groups. All current 
16 
prescribed  and  over  the  counter        medications will be documented. Patients will be allocated to the 
17 
treatment or placebo arms by simple randomization. BP will be measured in the right arm of patients, in 
18 
the seated position, using arm cuff and automated office blood pressure by oscillometry method.  Three 
19 
measurements will be taken one minute apart, and the average of each of the systolic and diastolic 
20 
measurements will be charted as the blood pressure recording for the visit. Pregnancy and breast feeding 
21 
status will be established by self-reporting by female patients. 
22 
Patients in the treatment arm will be started on IMN 60 mg ER daily. The dose of  IMN will be 
23 
escalated to 120 mg ER (two tablets of 60 mg ER) after 4 weeks of start of therapy, if no      response as 
24 
per our response criteria  ( as below) is achieved. The grace period for follow up appointments would be 
25 
+/- 3days to account for clinic closure, weather changes or patient’s inability to come to clinic due to 
26 
non-medical reasons. 
27 
The drug and placebo will be compounded in Compounding Shop Pharmacy, 11845 Wilcrest Dr, 
28 
Houston, TX 77031. Even though we will be using the drug for a non-FDA approved use of IMN, we 
29 
will not be needing IND for the study drug due to the low risk profile of the drug. Drug accountability 
30 
by IDS will include for storage, labeling, dispensing and disposal of the study drug and placebo. 
31 
Criteria for Response (one or more of the following) 
32 
1. 
Improved eGFR ≥25% from prior to enrollment. 
33 
2. 
Reduction in proteinuria of ≥25% from prior to enrollment. 
34 
3. 
Reduction in SBP of ≥ 10 mm Hg and/or DBP ≥ 5 mm Hg from prior to enrollment 
35 
Study design: 
36 
The patients will be allocated by simple randomized into the two groups (20 patients     per group). The 
37 
study will be double-blinded 
38 
Group  1: (Treatment group). The starting dose will be Imdur 60  mg  ER  daily and after   4  weeks,   if 
39 
tolerated but response is not achieved, the dose will be escalated to Imdur 120 mg ER daily (2 tabs  of 
40 
60 mg ER tablets).  This  would  be  done  in  addition  to  the  standard  of  care  treatment  with  either 
41 
angiotensin  converting  enzyme inhibitor (ACEI) or calcium channel blockers to treat hypertension   as 
42 
needed. 
43 
Group 2 :( Placebo group): Placebo will be given along with the standard of care treatment with 
44 
either ACE I or calcium channel blockers to treat hypertension as needed. The tablets of placebo will 
45 
be  doubled  after  4  weeks  of  start  of  therapy. This  will  help  eliminate bias in this double-blinded 
46 
study. 

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
15 
 
 
1 
2 
Follow-up: Systolic BP will be monitored on a weekly basis for three months. The patients will 
3 
record their BPs at home with their automated machines and will either call in with the results or   bring 
4 
their   records during the  next clinic visit. The eGFR  and  serum  creatinine  (included  in  the     basic 
5 
metabolic  panel)  will  be  measured  as  per  protocol   laboratory  workup  done  within  15  days     of 
6 
enrollment.  This  will  be  done  once  a  month  during  clinic  visits.  The  grace  period  for  follow up 
7 
appointments would be +/- 3 days to account for clinic closure, weather changes or patient’s inability to 
8 
come to clinic due to non-medical reasons. A follow up phone  call will be done every month (weeks 6, 
9 
10, 14 and 17 weeks) for 3 months. Antihypertensive medications that  the patients have  been     taking 
10 
prior  to enrollment will  be  continued. Any reduction in the need for antihypertensive medications will 
11 
be documented. UPC will be measured at the time of enrollment and then monthly. 
12 
13 
Primary End Points: 
14 
 
Reduction in UPC  of ≥25% from that  measured before  enrollment 
15 
Secondary End Points: 
16 
 
Improved eGFR ≥25% from before enrollment. 
17 
 
Reduction in SBP of ≥ 10 mm Hg and/or DBP ≥ 5 mm Hg from before enrollment 
18 
19 
Both the primary and secondary outcomes will be measured for every month for the 3 months that the 
20 
patient is in the trial. All patients will continue treatment for the entire 3 months to help with data analysis 
21 
for future larger randomized controlled studies. The grace period for follow up appointments would   be 
22 
+/- 3days to account for clinic closure, weather changes or patient’s inability to come to clinic due to 
23 
non-medical reasons. 
24 
MONITORING/ EVALUATION DURING STUDY: 
25 
Baseline BP, serum creatinine, eGFR, and UPC will be recorded  at the time of enrollment. For  blood 
26 
testing  2cc  of  serum  will  be  collected  and  for  urine  testing  2   ml  of  urine  will   be 
27 
collected, and  sent to  the  Memorial Herman outpatient laboratory.   Blood pressure   will 
28 
be monitored on a weekly basis starting from the time of      enrollment. In those who are already on BP 
29 
medications, BPs will be  recorded on a weekly basis, and  any  need  for  reduction/increase  in    the 
30 
doses/addition of new medications will be document. P a t i e n t s  w i l l  b e  g i v e n  a  l o g  b o o  k 
31 
t o  r e c o r d  t h e i r  B P s .  Patients  will  be  monitored for 3 months. UPC and serum creatinine will 
32 
be measured on a monthly basis. 
33 
If  side effects (nausea, dizziness, headache, symptomatic hypotension) are  observed  to the   increased 
34 
dose of 120 mg/day, the dose will be reduced back to the 60 mg d. 
35 
Confidentiality Plan: 
36 
All  data  obtained,  including  concomitant medications will  be entered in Red Cap. All serious adverse 
37 
events will be forwarded to FDA according to the UT Health Science Center at Houston institutional 
38 
policy. All records will be maintained at UT Heath Science center. The Data Safety Monitoring board 
39 
will be involved in safety monitoring. 
40 
Possible Side Effects: 
41 
Minor side effects of Imdur  have been noted,    including headache, dizziness, hypotension and nausea. 
42 
As per FDA approved package insert, headache and dizziness was reported in >5% of the patients. These 
43 
symptoms are dose dependent and tend to disappear with continued use. 
44 

IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019 
16 
 
 
1 
Criteria for Removal: 
2 
With the increased dose of Imdur, if side effects such as symptomatic  hypotension,  nausea,  headache 
3 
or dizziness the dose will be reduced to 60 mg ER. If it is the starting dose (60 mg ER) which caused 
4 
these effects, then the patient will be taken off the drug, and will be observed for Intension to Treat 
5 
(ITT)  analysis. The Severe Adverse Effect (SAE) will be reported according to the UT Health  Science 
6 
Center at Houston institutional      policy. Criteria for removal would be uncontrolled nausea, headache, 
7 
symptomatic  hypotension or dizziness.       We will also monitor for any worsening of renal function or 
8 
proteinuria. 
9 
Limitations: 
10 
This is a pilot study and therefore it is may not be powered to detect difference with treatment. The small 
11 
sample size may not allow the data to be statistically significant. It is unclear if other antihypertensive 
12 
medications will confound the results. Once preliminary data is available, the study population will   be 
13 
increased for a larger clinical trial. 
14 
15 
Expected results: 
16 
There will be statistically significant response seen with therapy in the patients. The study is a pilot study 
17 
and 
will 
help 
in 
establishing 
the 
basis 
of 
a 
larger 
randomized 
controlled 
study. 

 
REFERENCES: 
 
 
1. 
Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal 
toxicity. Current Oncol Rep. 2012;14:285-294. 
 
2. 
Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for        the 
hypotensive effect of VEGF. Hypertension. 2002;39:1095–1100. 
 
3. 
Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth 
factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359–1365. 
 
4. 
Johal T, Lees CC, Everett TR, Wilkinson IB. British J Clin Pharmacol. 2014;78(2):244-57. 
The nitric oxide pathway and possible therapeutic options in pre-eclampsia. 
 
5. 
Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, Hernández-Sierra JF, Rodríguez- 
Martínez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a 
randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol 2008; 35: 580–5. 
 
6. 
Trapani A Jr, Gonçalves LF, Pires MM. Transdermal nitroglycerin in patients with severe pre- 
eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery 
resistance indices. Ultrasound Obstet Gynecol 2011; 38: 389–94. 
 
7. 
Luzi G, Caserta G, Iammarino G, Clerici G, Di Renzo GC. Nitric oxide donors in pregnancy: 
fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. 
Ultrasound Obstet Gynecol 1999; 14: 101–9. 
 
8. 
Garovic VD, Wagner SJ, Petrovic LM, et al. Glomerular expression of nephrin and synaptopodin, 
but not podocin, is decreased in kidney sections from women with  preeclampsia. Nephrol Dial 
Transplant. 2007;22:1136–1143 
9. 
Bhavina K, Radhika J, Pandian SS. VEGF and eNOS expression in umbilical cord from 
pregnancy complicated by hypertensive disorder with different severity. Biomed Res Int 2014; 
2014:98215 
 
10. 
Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the 
prevention 
and 
treatment 
of 
angiogenesis-inhibitor-induced 
hypertension. 
Angiogenesis. 2013;16(2):289-95. 
 
11. 
Kruzliak P, Novák J, Novák M. Vascular endothelial growth factor inhibitor-induced 
hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. 
Am J  Hypertens. 2014;27(1):3-13 
12. 
Kaufman  R1, Nunes  I, Bolognese  JA  et  al.  Single-dose  effects   of isosorbide   mononitrate 
alone or in combination with losartan on central blood pressure. J Am Soc Hypertens. 2010 
;4(6):311-8 
13. 
Stokes GS1, Bune AJ, Huon N, Barin ES. Long-term effectiveness of extended-release nitrate 
for the treatment of systolic hypertension. Hypertension. 200;45(3):380-4. 
 
 
 
 
IRB NUMBER: HSC-MS-19-0429 
IRB APPROVAL DATE: 10/24/2019